Lead program
Pancreas
Locally advanced and borderline unresectable pancreatic ductal adenocarcinoma.
BetaGlue is building the local control platform designed to answer it.
Why local control matters more, not less
Improving systemic therapy does not make the primary tumor less important. It makes it more visible.
When systemic disease is controlled for longer, local progression becomes a leading cause of clinical deterioration — pain, biliary and duodenal obstruction, loss of eligibility for further treatment. Patients who respond well systemically can still be limited by a primary tumor that was never addressed.
As systemic therapies improve, durable local control becomes increasingly important.
Treatment landscape
How pancreatic cancer treatment is evolving
Each generation of therapy has extended what is possible — and revealed what remains unresolved.
Chemotherapy
Multi-agent regimens established systemic disease control as the backbone of care.
Targeted agents
Molecular characterisation opened the way to treating tumor biology, not only tumor burden.
KRAS inhibitors
A new generation of inhibitors is entering clinical development against one of the defining drivers of the disease.
Local control
As systemic disease is better controlled, durable control of the primary tumor becomes a decisive clinical challenge.
The ambition
Improved long-term outcomes — combining effective systemic therapy with durable local control is where the field is heading.
Our role
Building the local control platform
BetaGlue develops YntraDose®, a one-time, image-guided intratumoral Y-90 radiotherapeutic designed to deliver a high local radiation dose directly within the tumor.
Its mechanism is physical rather than molecular. It is designed to act independently of the mutational profile of the tumor, and to be delivered without interrupting the systemic treatment the patient is already receiving.
This is what makes local control a platform rather than a product: the same principle applies wherever a solid tumor remains locally advanced, difficult to resect, and resistant to systemic therapy alone.
One principle, multiple tumor types
Locally advanced pancreatic cancer is where the need is most acute, and it leads our clinical development. The underlying approach is not specific to it.
Liver
Unresectable early-stage hepatocellular carcinoma, and unresectable liver metastases.
Breast
Resectable early-stage disease, including ductal carcinoma in situ.
Our ambition
To make durable local tumor control a standard component of future precision oncology.
YntraDose® is an investigational radiotherapeutic. Its safety and performance are being evaluated in clinical development and have not been established.